Tysabri's Physician Uptake Remains Question Mark
Earlier this month when Biogen Idec Inc. at last unveiled one-year data from its Phase III trial known as AFFIRM, hopes of investors - not to mention multiple sclerosis patients - ran high for the would-be blockbuster Antegren (natalizumab).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter